DOCSLIB.ORG

LF-117708-01 Hydralazine 20Mg-Ml Injection V7

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
LF-117708-01 Hydralazine 20Mg-Ml Injection V7 Package leaflet: Information for the patient 28055763 syringe, this is called an intravenous injection or; • A restriction of movement in part of the intestine; LF-117708-01 - it may be diluted further and injected very slowly • A deficiency of certain white blood cells which into your vein through a drip (intravenous infusion). can result in fever and ulceration of the mouth The recommended dose is 5 to 10 mg by and throat; intravenous injection, and will be repeated if • An increased number of white blood cells; necessary after 20 to 30 minutes. • Enlargement of the spleen; Hydralazine 20mg Powder for Concentrate for Solution for Injection/Infusion • A reduction in the number of red and white blood Your blood pressure will be taken whilst you cells and platelets in the blood; Hydralazine hydrochloride are receiving treatment and the dose adjusted • Depression; to make sure that you have gradual fall in your Read all of this leaflet carefully before you start • have been told you are a slow acetylator • Seeing or hearing things which are not really blood pressure to normal levels. taking this medicine because it (this means that your body handles some there (hallucinations); contains important information for you medicines more slowly than other people); If you are given more medicine than you should • Inflammation of the nerves which may cause weakness - Keep this leaflet. You may need to read it again. • suffer from any serious liver or kidney problems; As this medicine is given to you in hospital it is very or numbness especially in your fingers and toes; - If you have any further questions ask your • have blockage of one or more arteries that supply unlikely that an overdose will happen. • Tingling (pins and needles) in your hands or feet; doctor, pharmacist or nurse. blood to the heart (coronary heart disease). Should an overdose occur, the doctor will treat any • Disease of the lymph nodes; - This medicine has been prescribed for you only. If any of the above apply to you, or if you are not symptoms that follow. • Enlarged eye balls; Do not pass it on to others. It may harm them, • The inability to completely or partially empty the sure, tell your doctor before receiving 4. POSSIBLE SIDE EFFECTS even if their symptoms are the same as yours. bladder; Hydralazine Injection. Like all medicines, this medicine can cause side - If you get any side effects, talk to your doctor, • Opposite effect of medical treatment (episodes of effects, although not everybody gets them. pharmacist or nurse. This includes any possible Children high blood pressure); side effects not listed in this leaflet. See section 4. Hydralazine Injection is not recommended for use in Stop taking the medicine and seek immediate • An increase in other kinds of white blood cells. children. medical advice if you notice the following: The name of your medicine is Hydralazine 20mg If you feel very tired, experience unexpected • SLE-type syndrome, which can cause symptoms Powder for Concentrate for Solution for Other medicines and Hydralazine Injection bruising or bleeding, or more infections (e.g. colds such as joint pain, fever, change in blood count Injection/Infusion referred to from now as Tell your doctor or pharmacist if you are taking, and sore throats) than usual please tell your doctor. and skin rash. Hydralazine Injection. have recently taken or might take any other Your doctor may decide to conduct tests on your • Allergic reactions including itching, skin rash, medicines. blood periodically as a result of these symptoms. What is in this leaflet: inflammation of the walls of small blood vessels It is especially important that you tell your doctor if 1. What Hydralazine injection is and what it is and difficulty in breathing. If any of the side effects becomes severe, or you you are taking: used for • Yellowing of the skin and whites of the eyes, notice any side effects not listed in this leaflet, • medicines for high blood pressure, such as 2. What you need to know before you are given which may indicate problems with the liver please tell your doctor or pharmacist vasodilators (e.g. minoxidil, diazoxide); Hydralazine Injection such as jaundice and hepatitis. immediately. • ACE inhibitors (e.g. enalapril, lisinopril, captopril); 3. How Hydralazine Injection is given • Kidney failure (e.g. changes in urine, swelling of • beta-blockers (e.g. propranolol); Reporting of side effects 4. Possible side effects legs, ankles or feet, shortness of breath, • calcium antagonists (e.g. nifedipine, diltiazem); If you get any side effects, talk to your doctor, 5. How to store Hydralazine Injection tiredness and nausea). • medicines for water retention (e.g. diuretics); pharmacist or nurse. This includes any possible side 6. Contents of the pack and other information • medicines for problems such as depression, Other side effects may include: effects not listed in this leaflet. You can also report 1. WHAT HYDRALAZINE INJECTION IS AND including monoamine oxidase inhibitors (MAOIs) Very common (may affect more than 1 in 10 side effects directly via the Yellow Card Scheme at: WHAT IT IS USED FOR (e.g. moclobemide, phenelzine, isocarboxazid, people) www.mhra.gov.uk/yellowcard or search for MHRA The name of your medicine is Hydralazine Injection. tranylcypromine), tricyclic antidepressants • Abnormal heart beat (palpitations); Yellow Card in the Google Play or Apple App Store The active ingredient is hydralazine hydrochloride (e.g. amitriptyline, clomipramine) or tranquillisers • An unusually fast heart beat; By reporting side effects you can help provide more in the form of a powder. Hydralazine hydrochloride (e.g. diazepam); • Headaches. information on the safety of this medicine. belongs to a group of medicines called • medicines to control pain and inflammation Common (may affect up to 1 in 10 people) 5. HOW TO STORE HYDRALAZINE INJECTION antihypertensives. (a group of medicines known as non-steroidal • Chest pains; Keep this medicine out of the sight and reach of anti-inflammatory drugs (NSAIDs)); Hydralazine Injection is used to treat very high blood • Swelling and/or pain in joints, muscle pain; children. • medicines to control psychoses; pressure, particularly when this condition occurs in • Low blood pressure; The ampoules will be stored in the hospital and they • a specific group of medicines known as nitrates, pregnancy or in people with kidney disease. • Feeling sick and being sick, particularly at will follow the instructions below. used to control blood pressure; It works by relaxing blood vessels which increases the beginning of the treatment or after The ampoules should be protected from light and • oestrogens (a group of female sex hormones the supply of blood and oxygen to the heart. an increase in dose; stored below 30°C. used in contraception and in treating the • Diarrhoea; Do not use this medicine after the expiry date which 2. WHAT YOU NEED TO KNOW BEFORE YOU ARE menopause). • Flushing. is stated on the label. The expiry date refers to the GIVEN HYDRALAZINE INJECTION If you are going to have a general anaesthetic Rare (may affect up to 1 in 1,000 people) last day of the month. The solution will be used as You should not be given this medicine if you: you should tell the doctor or dentist in charge • Heart failure, swelling; soon as it has been made up. • are allergic to hydralazine, dihydralazine or that you are taking Hydralazine Injection. any of the other ingredients in this medicine • Increased levels of a substance called creatinine 6. CONTENTS OF THE PACK AND OTHER Hydralazine Injection with food, drink and in the blood; (listed in section 6) (allergic reactions include • Breathlessness, breathing difficulties or pain INFORMATION mild symptoms such as itching and/or rash. alcohol when breathing; What Hydralazine Injection contains More severe symptoms include swelling of the It is advisable not to drink alcohol whilst taking • Skin rash; Each ampoule contains 20 mg of the active face, lips, tongue and/or throat with difficulty in Hydralazine Injection as it may affect you more • Blood in the urine which may be associated with ingredient, hydralazine hydrochloride as a powder. swallowing or breathing); than usual. a disease of the kidneys; They also contain hydrochloric acid (as an inactive • Presence of protein in the urine; ingredient). • have or have ever had a condition called Pregnancy, breast-feeding and fertility • Inflammation or the abnormal functioning of the liver; Systemic Lupus Erythematosus (SLE), an If you are pregnant or breast-feeding, think you may • Watering or sore itchy eyes; What Hydralazine Injection looks like and autoimmune condition which causes joint pain, be pregnant or are planning to have a baby, ask • A reduction in the number of platelets in the blood contents of the pack skin rashes and fever; which can cause unexplained bruising or rashes; your doctor or pharmacist for advice before taking Hydralazine Injection is provided as a white to • suffer from severe tachycardia or right sided • A reduction in red blood cells, which can make this medicine. yellow powder in 2 ml clear glass ampoules. heart failure due to increased pressure in the you feel tired or breathless with physical exertion; Driving and using machines • A reduction in certain white blood cells which Each pack contains 5 ampoules. blood vessels of the lungs (cor pulmonale); may make you more susceptible to infections; • suffer from thyrotoxicosis (an excess of thyroid You can drive while being treated with Hydralazine Marketing Authorisation Holder and Injection but do not drive until you know how it affects • Fever; hormones in the blood that can cause a fast • Anxiety; Manufacturer heartbeat, sweating, trembling, anxiety, increased you. It may make you feel dizzy or impair your • Restlessness; Amdipharm UK Limited, appetite, loss of weight and intolerance of heat); reactions.
Load more

Recommended publications
  • Dopamine: a Role in the Pathogenesis and Treatment of Hypertension
    Journal of Human Hypertension (2000) 14, Suppl 1, S47–S50 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh Dopamine: a role in the pathogenesis and treatment of hypertension MB Murphy Department of Pharmacology and Therapeutics, National University of Ireland, Cork, Ireland The catecholamine dopamine (DA), activates two dis- (largely nausea and orthostasis) have precluded wide tinct classes of DA-specific receptors in the cardio- use of D2 agonists. In contrast, the D1 selective agonist vascular system and kidney—each capable of influenc- fenoldopam has been licensed for the parenteral treat- ing systemic blood pressure. D1 receptors on vascular ment of severe hypertension. Apart from inducing sys- smooth muscle cells mediate vasodilation, while on temic vasodilation it induces a diuresis and natriuresis, renal tubular cells they modulate sodium excretion. D2 enhanced renal blood flow, and a small increment in receptors on pre-synaptic nerve terminals influence nor- glomerular filtration rate. Evidence is emerging that adrenaline release and, consequently, heart rate and abnormalities in DA production, or in signal transduc- vascular resistance. Activation of both, by low dose DA tion of the D1 receptor in renal proximal tubules, may lowers blood pressure. While DA also binds to alpha- result in salt retention and high blood pressure in some and beta-adrenoceptors, selective agonists at both DA humans and in several animal models of hypertension. receptor classes have been studied in the treatment of
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Hypertensive Crises 8.25
    Hypertensive Crises 8.25 Hypertension crises secondary to monoamine oxidase inhibitor–tyramine interactions Monoamine oxidase inhibitor therapy Impaired degradation of intracellular amines Ingestion of (epinephrine, norepinephrine, dopamine) tyramine-containing food Accumulation of catecholamines in Hepatic monamine nerve terminal storage granules oxidase inhibition with decreased Increased circulating oxidative metabolism tyramine level of tyramine Massive release of catecholamines Tachyarrhythmias Vasoconstriction (increased systemic vascular resistance) Severe paroxysm of hypertension Hypertensive encephalopathy Acute hypertensive heart failure with pulmonary edema Intracerebral hemorrhage (Fig. 8-21) (Figs. 8-24 and 8-25) FIGURE 8-32 Hypertensive crises secondary to monoamine oxidase inhibitor–tyramine interactions. Severe paroxysmal hypertension complicated by intracerebral or subarachnoid hemorrhage, hypertensive encephalopathy, or acute hypertensive heart failure can occur in patients treated with monoamine oxidase (MOA) inhibitors after ingestion of certain drugs or tyramine- containing foods [48,49]. Because MAO is required for degradation of intracellular amines, including epinephrine, norepinephrine, and dopamine, MAO inhibitors lead to accumulation of catecholamines within storage granules in nerve terminals. The amino acid tyramine is a potent inducer of neurotransmitter release from nerve terminals. As a result of inhibition of hepatic MAO, ingested tyramine escapes oxidative degradation in the liver. In addition, the high circulating levels of tyramine provoke massive catecholamine release from nerve terminals, resulting in vasoconstriction and a paroxysm of severe hypertension. A hyper- adrenergic syndrome resembling pheochromocytoma then ensues. Symptoms include severe pounding headache, flushing or pallor, profuse diaphoresis, nausea, vomiting, and extreme prostration. The mean increase in blood pressure is 55 mm Hg systolic and 30 mm Hg diastolic [49]. The duration of the attacks varies from 10 minutes to 6 hours.
    [Show full text]
  • Toxicological Profile for Hydrazines. US Department Of
    TOXICOLOGICAL PROFILE FOR HYDRAZINES U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Agency for Toxic Substances and Disease Registry September 1997 HYDRAZINES ii DISCLAIMER The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry. HYDRAZINES iii UPDATE STATEMENT Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at: Agency for Toxic Substances and Disease Registry Division of Toxicology/Toxicology Information Branch 1600 Clifton Road NE, E-29 Atlanta, Georgia 30333 HYDRAZINES vii CONTRIBUTORS CHEMICAL MANAGER(S)/AUTHOR(S): Gangadhar Choudhary, Ph.D. ATSDR, Division of Toxicology, Atlanta, GA Hugh IIansen, Ph.D. ATSDR, Division of Toxicology, Atlanta, GA Steve Donkin, Ph.D. Sciences International, Inc., Alexandria, VA Mr. Christopher Kirman Life Systems, Inc., Cleveland, OH THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS: 1 . Green Border Review. Green Border review assures the consistency with ATSDR policy. 2 . Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points. 3. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs. HYDRAZINES ix PEER REVIEW A peer review panel was assembled for hydrazines. The panel consisted of the following members: 1. Dr.
    [Show full text]
  • Guideline for Preoperative Medication Management
    Guideline: Preoperative Medication Management Guideline for Preoperative Medication Management Purpose of Guideline: To provide guidance to physicians, advanced practice providers (APPs), pharmacists, and nurses regarding medication management in the preoperative setting. Background: Appropriate perioperative medication management is essential to ensure positive surgical outcomes and prevent medication misadventures.1 Results from a prospective analysis of 1,025 patients admitted to a general surgical unit concluded that patients on at least one medication for a chronic disease are 2.7 times more likely to experience surgical complications compared with those not taking any medications. As the aging population requires more medication use and the availability of various nonprescription medications continues to increase, so does the risk of polypharmacy and the need for perioperative medication guidance.2 There are no well-designed trials to support evidence-based recommendations for perioperative medication management; however, general principles and best practice approaches are available. General considerations for perioperative medication management include a thorough medication history, understanding of the medication pharmacokinetics and potential for withdrawal symptoms, understanding the risks associated with the surgical procedure and the risks of medication discontinuation based on the intended indication. Clinical judgement must be exercised, especially if medication pharmacokinetics are not predictable or there are significant risks associated with inappropriate medication withdrawal (eg, tolerance) or continuation (eg, postsurgical infection).2 Clinical Assessment: Prior to instructing the patient on preoperative medication management, completion of a thorough medication history is recommended – including all information on prescription medications, over-the-counter medications, “as needed” medications, vitamins, supplements, and herbal medications. Allergies should also be verified and documented.
    [Show full text]
  • Hydralazine Hydrochloride Tablets, USP8073301/1120Rx Only
    HYDRALAZINE HYDROCHLORIDE- hydralazine hydrochloride tablet, film coated American Health Packaging ---------- Hydralazine Hydrochloride Tablets, USP 8073301/1120 Rx only DESCRIPTION HydrALAZINE hydrochloride, USP, is an antihypertensive, for oral administration. Its chemical name is 1-hydrazinophthalazine monohydrochloride, and its structural formula is: HydrALAZINE hydrochloride, USP is a white to off-white, odorless crystalline powder. It is soluble in water, slightly soluble in alcohol, and very slightly soluble in ether. It melts at about 275°C, with decomposition, and has a molecular weight of 196.64. Each tablet for oral administration contains 10 mg, 25 mg, 50 mg, or 100 mg hydrALAZINE hydrochloride, USP. Tablets also contain FD&C Red #40/Allura Red AC Aluminum Lake, hypromellose, lactose anhydrous, light mineral oil, microcrystalline cellulose, magnesium stearate, pregelatinized starch, sodium lauryl sulfate, and titanium dioxide. CLINICAL PHARMACOLOGY Although the precise mechanism of action of hydrALAZINE is not fully understood, the major effects are on the cardiovascular system. HydrALAZINE apparently lowers blood pressure by exerting a peripheral vasodilating effect through a direct relaxation of vascular smooth muscle. HydrALAZINE, by altering cellular calcium metabolism, interferes with the calcium movements within the vascular smooth muscle that are responsible for initiating or maintaining the contractile state. The peripheral vasodilating effect of hydrALAZINE results in decreased arterial blood pressure (diastolic more than systolic); decreased peripheral vascular resistance; and an increased heart rate, stroke volume, and cardiac output. The preferential dilatation of arterioles, as compared to veins, minimizes postural hypotension and promotes the increase in cardiac output. HydrALAZINE usually increases renin activity in plasma, presumably as a result of increased secretion of renin by the renal juxtaglomerular cells in response to reflex sympathetic discharge.
    [Show full text]
  • Drugs Associated with an Increased Falls Risk
    DRUGS ASSOCIATED WITH INCREASED FALL RISK Beverly Hospital PSYCHOTROPICS PSYCHOTROPICS ANTIHYPERTENSIVES NARCOTICS Antidepressants Antipsychotics(Atypical) ACE Inhibitors Acetaminophen-Codeine- Citalopram (Celexa) Clozapine (Clozaril) Benazepril (Lotensin) Caffeine (Tylenol # 1/2/3) Fluoxetine (Prozac) Olanzapine (Zyprexa) Captopril (Capoter) Codeine Fluvoxamine (Luvox) Quetiapine (Seroquel) Perindopril (Coversy) Fentanyl (Sublimaze, Duragesi) Paroxetine (Paxit) Antipsychotics(Neuroleptics) Cilazapril (Inhibace) Hydromorphone (Dilaudid, Sentraline (Zoloft) Chiorpromazine (Largactil) Enalapril (Vasotec) Hydromorph Contin) Venlafaxine (Effexor) Haloperidol (Haldol) Ramipril (Altace) Meperidine (Demerol) Amitriptyline (Elavil) Hydroxyzine (Atarax) Lisinopril (Prinivil, Zestril) Morphine (MOS, MS Contin, Bupropion (Wellbutrin) Lithium Quinapril (Accupril) M-Eston) Clomipramine (Anafranit) Loxapine (Loxapac) Fosinopril (Monopril) Oxycodone (Percocel, Desipramine (Norpramin) Methotrimeprazine (Nozinan Beta Blockers Percodan, OxyContin) Doxepin (Sinequan) Perphenazine (Trilafon) Acebutolo (Sectrail) Pentazocine (Talwin) Imipramine (Tofranit) Prochlorperazine (Stemetil) Atenolol (Tenormin) Note: May be administered with Mirtazapine (Remeron) Risperidone (Resperdal) Bisoprolol (Monocor) dimenhydrinate (Gravol) or Moclobemide (Manerix) Thioridazine (Mellaril) Carvedilol (Coreg) prochlorperazine (Stemeo) which may increase side effects of drowsiness and Nortriptyline (Aventy) Trifluoperazine (Stelazine) Labetalol (Trandate) dizziness. Trazodone
    [Show full text]
  • Prescribed Drugs Containing Nitrogen Heterocycles: an Overview Cite This: RSC Adv., 2020, 10, 44247 Majid M
    RSC Advances View Article Online REVIEW View Journal | View Issue Prescribed drugs containing nitrogen heterocycles: an overview Cite this: RSC Adv., 2020, 10, 44247 Majid M. Heravi * and Vahideh Zadsirjan Heteroatoms as well as heterocyclic scaffolds are frequently present as the common cores in a plethora of active pharmaceuticals natural products. Statistically, more than 85% of all biologically active compounds are heterocycles or comprise a heterocycle and most frequently, nitrogen heterocycles as a backbone in their complex structures. These facts disclose and emphasize the vital role of heterocycles in modern drug design and drug discovery. In this review, we try to present a comprehensive overview of top Received 28th October 2020 prescribed drugs containing nitrogen heterocycles, describing their pharmacological properties, medical Accepted 23rd November 2020 applications and their selected synthetic pathways. It is worth mentioning that the reported examples are DOI: 10.1039/d0ra09198g actually limited to current top selling drugs, being or containing N-heterocycles and their synthetic rsc.li/rsc-advances information has been extracted from both scientific journals and the wider patent literature. Creative Commons Attribution 3.0 Unported Licence. 1. Introduction chloroquinine, azidothymidine and anti-pyrine. Furthermore, most of the vitamins, nucleic acid, enzymes, co-enzymes, hormones, and 13 Medicinal and pharmaceutical chemistry are disciplines at the alkaloids contain N-based heterocycles as scaffolds. intersection of chemistry, especially synthetic organic chemistry, and Due to exhibiting diverse biological activities, nitrogen pharmacology and various other biological specialties, leading to the heterocyclic compounds have always been attractive targets to design, chemical synthesis and development of bio-active molecules, synthetic organic chemists.
    [Show full text]
  • Hydralazine 25Mg and 50Mg Tablets
    Package leaflet: Information for the patient Hydralazine 25mg and 50mg tablets Read all of this leaflet carefully • have angina pectoris, which causes pain in the chest before you start taking this with exercise medicine because it contains • have cerebrovascular disease (narrowing of the blood vessels in the brain) important information for you. • have been told you are a slow acetylator (this means • Keep this leaflet. You may need to that your body handles some medicines more slowly read it again. than other people) • If you have any further questions, • suffer from any serious liver or kidney problems. ask your doctor or pharmacist. Tests • This medicine has been prescribed If you are taking long-term Hydralazine treatment, for you only. Do not pass it on to your doctor may want to carry out blood and urine others. It may harm them, even if tests every 6 months. their signs of illness are the same as yours. Other medicines and Hydralazine tablets • If you get any side effects, talk to Tell your doctor or pharmacist if you are taking, have your doctor or pharmacist. This recently taken or might take any other medicines. includes any possible side effects It is especially important to tell your doctor if you are not listed in this leaflet. See section taking: 4. • medicines for high blood pressure, such as vasodilators (e.g. minoxidil diazoxide) What is in this leaflet • ACE inhibitors (e.g. enalapril, lisinopril, captopril) • Beta-blockers (e.g. propranolol) 1 What Hydralazine tablets are • calcium antagonists (e.g. nifedipine or diltiazem) and what they are used for • medicines for water retention (e.g.
    [Show full text]
  • Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act
    Updated June 07, 2021 Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Three categories of bulk drug substances: • Category 1: Bulk Drug Substances Under Evaluation • Category 2: Bulk Drug Substances that Raise Significant Safety Risks • Category 3: Bulk Drug Substances Nominated Without Adequate Support Updates to Categories of Substances Nominated for the 503B Bulk Drug Substances List1 • Add the following entry to category 2 due to serious safety concerns of mutagenicity, cytotoxicity, and possible carcinogenicity when quinacrine hydrochloride is used for intrauterine administration for non- surgical female sterilization: 2,3 o Quinacrine Hydrochloride for intrauterine administration • Revision to category 1 for clarity: o Modify the entry for “Quinacrine Hydrochloride” to “Quinacrine Hydrochloride (except for intrauterine administration).” • Revision to category 1 to correct a substance name error: o Correct the error in the substance name “DHEA (dehydroepiandosterone)” to “DHEA (dehydroepiandrosterone).” 1 For the purposes of the substance names in the categories, hydrated forms of the substance are included in the scope of the substance name. 2 Quinacrine HCl was previously reviewed in 2016 as part of FDA’s consideration of this bulk drug substance for inclusion on the 503A Bulks List. As part of this review, the Division of Bone, Reproductive and Urologic Products (DBRUP), now the Division of Urology, Obstetrics and Gynecology (DUOG), evaluated the nomination of quinacrine for intrauterine administration for non-surgical female sterilization and recommended that quinacrine should not be included on the 503A Bulks List for this use. This recommendation was based on the lack of information on efficacy comparable to other available methods of female sterilization and serious safety concerns of mutagenicity, cytotoxicity and possible carcinogenicity in use of quinacrine for this indication and route of administration.
    [Show full text]
  • Using Medications, Cosmetics, Or Eating Certain Foods Can Increase Sensitivity to Ultraviolet Radiation
    USING MEDICATIONS, COSMETICS, OR EATING CERTAIN FOODS CAN INCREASE SENSITIVITY TO ULTRAVIOLET RADIATION. INDIVIDUALS SHOULD CONSULT A PHYSICIAN BEFORE USING A SUNLAMP, IF THEY ARE TAKING MEDICATIONS. THE ITEMS LISTED ARE POTENTIAL PHOTOSENSITIZING AGENTS THAT MAY INCREASE SENSITIVITY TO ULTRAVIOLET LIGHT THAT MAY RESULT IN A PHOTOTOXIC OR PHOTOALLERGIC RESPONSES. PHOTOSENSITIZING MEDICATIONS Acetazolamide Amiloride+Hydrochlorothizide Amiodarone Amitriptyline Amoxapine Astemizole Atenolol+Chlorthalidone Auranofin Azatadine (Optimine) Azatidine+Pseudoephedrine Bendroflumethiazide Benzthiazide Bromodiphenhydramine Bromopheniramine Captopril Captopril+Hydrochlorothiazide Carbaamazepine Chlordiazepoxide+Amitriptyline Chlorothiazide Chlorpheniramine Chlorpheniramin+DPseudoephedrine Chlorpromazine Chlorpheniramine+Phenylopropanolamine Chlorpropamide Chlorprothixene Chlorthalidone Chlorthalidone+Reserpine Ciprofloxacin Clemastine Clofazime ClonidineChlorthalisone+Coal Tar Coal Tar Contraceptive (oral) Cyclobenzaprine Cyproheptadine Dacarcazine Danazol Demeclocycline Desipramine Dexchlorpheniramine Diclofenac Diflunisal Ditiazem Diphenhydramine Diphenylpyraline Doxepin Doxycycline Doxycycline Hyclate Enalapril Enalapril+Hydrochlorothiazide Erythromycin Ethylsuccinate+Sulfisoxazole Estrogens Estrogens Ethionamide Etretinate Floxuridine Flucytosine Fluorouracil Fluphenazine Flubiprofen Flutamide Gentamicin Glipizide Glyburide Gold Salts (compounds) Gold Sodium Thiomalate Griseofulvin Griseofulvin Ultramicrosize Griseofulvin+Hydrochlorothiazide Haloperidol
    [Show full text]
  • Pharmacogenetic Studies on the Drug- Related Lupus Syndrome
    979 PHARMACOGENETIC STUDIES ON THE DRUG- RELATED LUPUS SYNDROME Differences in Antinuclear Antibody Development and Drug-Induced DNA Damage in Rapid and Slow Acetylator Animal Models W. W. WEBER and R. H. TANNEN Pharmacogenetic study of an inbred mouse acetylators may also be found in abnormally high num- model system derived from A/J (slow acetylator) and bers in certain groups of patients with spontaneous C57BL/6J (rapid acetylator) parental strains shows lupus erythematosus (8). These correlations have sug- that spontaneous occurrence of antinuclear antibodies gested more than a simple pharmacologic relation be- is associated with the slow acetylator phenotype al- tween drug-induced lupus and the slow acetylator though the development of spontaneous and pro- phenotype and we have devised new experimental ap- cainamide-induced antinuclear antibodies is a dis- proaches to seek such possibilities. sociable process. In another study using primary We have found from pharmacogenetic studies in cultures of intact hepatocytes obtained from slow and an inbred mouse model system that spontaneous occur- rapid acetylator rabbits, observations indicate that the rence of antinuclear antibodies (ANA) is associated amount of DNA damage induced by exposure to hydra- with the slow acetylator phenotype (9, lo), although the zine and arylamine containing foreign compounds de- development of spontaneous and procainamide-induced pends on the concentration of the foreign compound ANA is a dissociable process. Also, we have found that used as well as on the acetylator phenotype. Exposure the amount of drug-induced DNA damage in primary to hydralazine induced greater DNA damage in slow cultures of intact hepatocytes obtained from rapid and acetylator hepatocytes whereas exposure to the aryla- slow acetylator rabbits is dependent on the specific mine carcinogen, 2-aminofluorene, induced greater hydrazine drug or arylamine to which the hepatocytes DNA damage in rapid acetylator hepatocytes.
    [Show full text]